Well J as others have posted the medical tar, here and board is excellent and there are several trials on the horizon that would make the company and the oil sales will also likely increase . In relation to the ARDS trial phase one was successful , in vitro was successful so one would expect that phase 2 will be successful and once boxes ticked approval obtained the SP will reflect the rerate .
The point is that the BOD has not put a foot wrong they have delivered what they have said they would to date in very trying times of COVID and the ARDS results announced to date are excellent . So imo there is no indication that the results will not be positive and for the trial not to be successful and given what we know to date on the contrary it should follow through and on the company establishing efficacy of any of the trials it will re rate massively imo .
Excellent risk reward and imo undervalued on the oil sales alone at these levels . I am happy to be patient and to be invested in this company ,but each has to make their own decision according to their risk profile .AIMO .
IHL Price at posting:
5.9¢ Sentiment: Buy Disclosure: Held
